GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NFL Biosciences SA (XPAR:ALNFL) » Definitions » Asset Impairment Charge

NFL Biosciences (XPAR:ALNFL) Asset Impairment Charge : €0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NFL Biosciences Asset Impairment Charge?

NFL Biosciences's Asset Impairment Charge for the six months ended in Dec. 2023 was €0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00 Mil.


NFL Biosciences Asset Impairment Charge Historical Data

The historical data trend for NFL Biosciences's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NFL Biosciences Asset Impairment Charge Chart

NFL Biosciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
Get a 7-Day Free Trial - - - - -

NFL Biosciences Semi-Annual Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

NFL Biosciences Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.


NFL Biosciences Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of NFL Biosciences's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


NFL Biosciences (XPAR:ALNFL) Business Description

Traded in Other Exchanges
Address
199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.

NFL Biosciences (XPAR:ALNFL) Headlines

No Headlines